C 6 H 8 N4O, monoclinic, P21/c (no. 14), a = 8.019(5) Å, b = 9.990(6) Å, c = 9.050(6) Å, β = 98.474(10)°,
T = 296(2) K.
CCDC no.: 1854561
The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
The title compound was synthesized via methyl 5-methylpyrazine-2-carboxylate (1 mmol) with excess hydrazine hydrate (4 mmol) in methanol solution (5 mL) under refluxing. The crystal suitble for single X-ray diffraction was obtained by recrystallization from acetonitrile solution. 
Experimental details
The structure was solved by Direct Methods and refined with the SHELX crystallographic software package [2] . The hydrogen atoms were placed at calculated positions and refined as riding atoms with isotropic displacement parameters. pharmacological activities [3] . As part of our continuous work on pyrazine derivatives [4] , the title compound was synthesized and its crystal structure is presented here.
Discussion
There is one molecule in the asymmetric unit (cf. the figure). In the title compound, the bond length of the C=O double bond is 1.234(2) Å, comparable with the literatrue values [5] . Bond lengths and angles are comparable with those found in the crystal structure of a directly related pyrazine carboxy compound [6] . In the crystal, intermolecular N-H· · · O hydrogen bonds link the molecules into a chain-like structure along b axis.
